NASDAQ:GNMK - GenMark Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.96 +0.11 (+1.40 %)
(As of 09/25/2018 02:43 AM ET)
Previous Close$7.85
Today's Range$7.69 - $7.97
52-Week Range$3.63 - $9.87
Volume168,500 shs
Average Volume315,720 shs
Market Capitalization$437.66 million
P/E Ratio-6.58
Dividend YieldN/A
GenMark Diagnostics logoGenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments


Debt-to-Equity Ratio0.19
Current Ratio2.04
Quick Ratio1.80


Trailing P/E Ratio-6.58
Forward P/E Ratio-9.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$52.52 million
Price / Sales8.45
Cash FlowN/A
Price / CashN/A
Book Value$1.29 per share
Price / Book6.17


EPS (Most Recent Fiscal Year)($1.21)
Net Income$-61,850,000.00
Net Margins-91.58%
Return on Equity-87.96%
Return on Assets-50.38%


Outstanding Shares55,750,000
Market Cap$437.66 million

GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc (NASDAQ:GNMK) announced its quarterly earnings data on Monday, July, 30th. The medical equipment provider reported ($0.30) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.09. The medical equipment provider earned $14.94 million during the quarter, compared to analyst estimates of $14.74 million. GenMark Diagnostics had a negative net margin of 91.58% and a negative return on equity of 87.96%. View GenMark Diagnostics' Earnings History.

When is GenMark Diagnostics' next earnings date?

GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for GenMark Diagnostics.

What price target have analysts set for GNMK?

5 Wall Street analysts have issued 1 year target prices for GenMark Diagnostics' shares. Their predictions range from $10.00 to $11.00. On average, they anticipate GenMark Diagnostics' stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics.

What is the consensus analysts' recommendation for GenMark Diagnostics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GenMark Diagnostics.

What are Wall Street analysts saying about GenMark Diagnostics stock?

Here are some recent quotes from research analysts about GenMark Diagnostics stock:
  • 1. Needham & Company LLC analysts commented, "GNMK’s 2Q18 revenue beat while its EPS missed consensus. Management reiterated its 2018 revenue and ePlex placement guidance. GNMK placed 39 ePlex systems in 2Q18, up from 32 in 1Q18 and above our estimate of 35. Increased utilization drove consumables revenue growth and GNMK’s gross margin improved from 1Q18. We believe the 2Q18 results are further evidence that the ePlex launch is gaining momentum. We continue to expect increased utilization of a growing ePlex installed base to continue to drive strong revenue growth (and eventually, improved gross margins) and we reiterate our Buy rating." (7/31/2018)
  • 2. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (7/18/2018)
  • 3. BTIG Research analysts commented, "The fact that ACOR announced this morning that it will discontinue the tozadenant program (stopping dosing in all currently enrolled studies) came as little surprise following last week’s disclosure of safety issues (our thoughts here). Timing was the only marginal surprise, but based on additional analyses, the company determined that the recently instituted weekly white blood cell count screening may not be adequate to fully ensure the safety of patients. Though this morning’s headline has little incremental impact, it does highlight the added pressure on Inbrija (which is delayed itself following the RTF earlier this year) and formally removes the potential for near- term leverage in the business. Maintain Neutral." (11/20/2017)

Who are some of GenMark Diagnostics' key competitors?

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the folowing people:
  • Mr. Hany Massarany, CEO, Pres & Director (Age 57)
  • Mr. Scott Mendel, Chief Financial Officer (Age 51)
  • Ms. Jennifer Williams, Sr. VP of HR (Age 45)
  • Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 43)
  • Mr. Brian Andrew Mitchell, Sr. VP of Operations (Age 53)

Who are GenMark Diagnostics' major shareholders?

GenMark Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.91%), Cadian Capital Management LP (8.04%), Putnam Investments LLC (6.63%), Casdin Capital LLC (6.10%), BlackRock Inc. (6.02%) and Millennium Management LLC (1.33%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, Jennifer Anne Williams, Jon Faiz Kayyem, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.

Which institutional investors are selling GenMark Diagnostics stock?

GNMK stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Cadian Capital Management LP, Casdin Capital LLC, Granite Investment Partners LLC, Jennison Associates LLC, Bank of New York Mellon Corp, Bank of New York Mellon Corp and Royce & Associates LP. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, Jennifer Anne Williams, Michael Gleeson and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.

Which institutional investors are buying GenMark Diagnostics stock?

GNMK stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Bradley Foster & Sargent Inc. CT, Private Wealth Partners LLC, Citadel Advisors LLC, Needham Investment Management LLC, Schwab Charles Investment Management Inc. and FMR LLC. View Insider Buying and Selling for GenMark Diagnostics.

How do I buy shares of GenMark Diagnostics?

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GNMK stock can currently be purchased for approximately $7.96.

How big of a company is GenMark Diagnostics?

GenMark Diagnostics has a market capitalization of $437.66 million and generates $52.52 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.

What is GenMark Diagnostics' official website?

The official website for GenMark Diagnostics is

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]

MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  348 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  550
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by Staff

Featured Article: Do Tariffs Work?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel